Important Notice: Opine Online provides an
informal way for the research community to express its views on current topics.
The results are not a scientific poll and do not necessarily reflect the percentages
of all Alzheimer researchers who agree with these positions.
Poll Question: A year has passed since Dale Schenk and his colleagues at Elan Phamaceuticals startled the research community with their Nature paper showing that vaccination with A-beta peptide reduces plaque deposition in PDAPP transgenic mice. Subsequent studies indicate that the vaccine can also prevent several transgenic mouse models of AD from developing deficits in spatial memory. No adverse side-effects have been reported by Elan in human safety trials to date. If the vaccine reaches Phase II clinical trials, the results could provide a conclusive answer to a central question: Is A-beta necessary and sufficient to cause Alzheimer's disease?
The BAPtists were right.
A-beta is necessary but not sufficient.
A-beta is a side product of whatever is really causing AD.